home / lobbying / lobbying_filings_raw

lobbying_filings_raw: 3b3d64e7-7e64-40cc-afcd-e78794345f22

Raw lobbying disclosure filings from the Senate Office of Public Records (SOPR). Each row is a single filing — registrations, quarterly reports, amendments, and terminations. Includes registrant and client names, reported income/expenses, filing period, and the full raw JSON from the API.

This data as json

filing_uuid filing_type registrant_id registrant_name client_id client_name filing_year filing_period received_date amount_reported is_amendment is_no_activity is_termination raw_json
3b3d64e7-7e64-40cc-afcd-e78794345f22 Q3 40036301 KNIGHT CAPITOL CONSULTANTS 188331 GENZYME CORPORATION 2013 third_quarter 2013-10-16T19:33:34.300000-04:00 40000.0 0 0 0 {"url": "https://lda.senate.gov/api/v1/filings/3b3d64e7-7e64-40cc-afcd-e78794345f22/", "filing_uuid": "3b3d64e7-7e64-40cc-afcd-e78794345f22", "filing_type": "Q3", "filing_type_display": "3rd Quarter - Report", "filing_year": 2013, "filing_period": "third_quarter", "filing_period_display": "3rd Quarter (July 1 - Sep 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/3b3d64e7-7e64-40cc-afcd-e78794345f22/print/", "filing_document_content_type": "text/html", "income": "40000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Patricia Knight, President", "dt_posted": "2013-10-16T19:33:34.300000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "750 17th Street, NW, Suite 1100", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "Washington,", "registrant_state": "DC", "registrant_zip": "20006", "registrant": {"id": 40036301, "url": "https://lda.senate.gov/api/v1/registrants/40036301/", "house_registrant_id": 39935, "name": "KNIGHT CAPITOL CONSULTANTS", "description": "Government Relations", "address_1": "817 North Lincoln Street", "address_2": null, "address_3": null, "address_4": null, "city": "Arlington", "state": "VA", "state_display": "Virginia", "zip": "22201", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "PATRICIA KNIGHT", "contact_telephone": "+1 202-510-5264", "dt_updated": "2026-03-04T13:51:53.437656-05:00"}, "client": {"id": 188331, "url": "https://lda.senate.gov/api/v1/clients/188331/", "client_id": 12, "name": "GENZYME CORPORATION", "general_description": "Genzyme is a leading biotechnology enterprise which focuses on rare disorders or diseases.", "client_government_entity": false, "client_self_select": false, "state": "MA", "state_display": "Massachusetts", "country": "US", "country_display": "United States of America", "ppb_state": null, "ppb_state_display": null, "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2008-02-01"}, "lobbying_activities": [{"general_issue_code": "TAX", "general_issue_code_display": "Taxation/Internal Revenue Code", "description": "Possible changes in the tax code that affect the pharmaceutical industry, including the R&D tax credit and the Orphan Drug tax credit.", "foreign_entity_issues": "As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.", "lobbyists": [{"lobbyist": {"id": 40329, "prefix": null, "prefix_display": null, "first_name": "PATRICIA", "nickname": null, "middle_name": null, "last_name": "KNIGHT", "suffix": null, "suffix_display": null}, "covered_position": "previously listed", "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "Implementation of, and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and the Independent Payment Advisory Board. General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs, reimbursement for pharmaceuticals under Medicare Parts B and D, and 340B clinics.", "foreign_entity_issues": "As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.", "lobbyists": [{"lobbyist": {"id": 40329, "prefix": null, "prefix_display": null, "first_name": "PATRICIA", "nickname": null, "middle_name": null, "last_name": "KNIGHT", "suffix": null, "suffix_display": null}, "covered_position": "Prof Staff, House Appropriations Committee", "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "Budget and deficit reduction proposals that may affect the Medicare and Medicaid programs, including issues related to End Stage Renal Disease, and Sustainable Growth Rate and Average Sales Price calculations.", "foreign_entity_issues": "As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.", "lobbyists": [{"lobbyist": {"id": 40329, "prefix": null, "prefix_display": null, "first_name": "PATRICIA", "nickname": null, "middle_name": null, "last_name": "KNIGHT", "suffix": null, "suffix_display": null}, "covered_position": "(previously listed)", "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "Adequate funding for programs of the Food and Drug Administration, including implementation of the Prescription Drug User Fee Act (FY 2014 appropriations for the FDA, H.R. 2410/S. 1244/H.J. Res. 59). Assess potential impact of sequestration on public health/food and drug programs (FY 2014 appropriations for HHS, S. 1284).", "foreign_entity_issues": "As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.", "lobbyists": [{"lobbyist": {"id": 40329, "prefix": null, "prefix_display": null, "first_name": "PATRICIA", "nickname": null, "middle_name": null, "last_name": "KNIGHT", "suffix": null, "suffix_display": null}, "covered_position": "(previously listed)", "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []}

Links from other tables

  • 4 rows from filing_uuid in lobbying_activities
  • 1 row from filing_uuid in lobbying_lobbyists
Powered by Datasette · Queries took 16.365ms